-
Most Popular
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028!
What Are the Hottest Biotech Stocks Right Now? 3 Top Picks.
Figuring out the hottest biotech stocks can be as simple as looking at the most traded stocks by volume in the last 24 hours.
3 Biotech Stocks That Could Have Investors Grinning Soon
Biotech stocks are a high risk, high reward investment and these three biotechs offer significant upside potential.
DNA Stock Alert: Ginkgo Bioworks Plunges on Plan for Reverse Stock Split
Ginkgo Bioworks stock is falling hard on Friday as DNA investors prepare to vote on a reverse stock split later this month.
ME Stock Alert: CEO Anne Wojcicki Enters $200 Million Buyout Offer for 23andMe
23andMe stock is up on Friday as investors react to an offer from the company's founder to take it private for 40 cents per share for ME.
Why Is Akanda (AKAN) Stock Up 34% Today?
Akanda stock is on the rise Friday alongside heavy pre-market trading of AKAN shares and a lack of news this morning.
Why Is VSee Health (VSEE) Stock Up 172% Today?
VSee Health stock is up on Friday after the company announced plans to develop a robot for the inpatient intensive care market.
Get Your Money Out of These 3 Healthcare Stocks ASAP
Many companies in the healthcare sector have great outlooks but these healthcare stocks to sell are facing very tough challenges
3 AI-Powered Healthcare Stocks Transforming Medicine
Invest in AI healthcare stocks to benefit significantly from tech that could propel the healthcare market to $148.4 billion by 2029.
Why is Immuneering (IMRX) Stock Up 24% Today?
Up nearly 25% in today's session on a fast track designation for a key pancreatic cancer drug candidate, IMRX stock is coming into focus.
Arbutus Layoffs 2024: What to Know About the Latest ABUS Job Cuts
While the Arbutus layoffs represents a major overhaul operationally, the market has responded positively to ABUS stock. Here’s why.
Why Is RedHill Biopharma (RDHL) Stock Up 75% Today?
One of today's biggest market movers in the biotech space is RedHill Biuopharma, with RDHL stock up more than 75% on big news.
3 Tech Stocks to Sell Before You Regret It
Run don't walk from these troubled technology companies. These are the tech stocks to sell to avoid pain and sorrow.
7 Leading MedTech Stocks for Next-Gen Health Solutions
With healthcare innovations promising to deliver groundbreaking solutions, these MedTech stocks should be on your radar.
FibroGen Layoffs 2024: What to Know About the Latest FGEN Job Cuts
FibroGen layoffs are in the news Wednesday after the biopharmaceutical company announced plans to cut jobs after failed clinical trials.
7 Top Stocks Under $10: July 2024 Edition
There are more than 2,100 stocks under $10 from which to choose in the market. If you want to find the best, use the Portfolio Grader.
Why is Macrogenics (MGNX) Stock Down 28% Today?
Macrogenics stock is down on Wednesday after MGNX investors learned that the company is discontinuing a Phase 2 clinical trial.
